2.Advances in Solid-state Fermentation of Microbial Lipase
Xiao-Feng WANG ; Yun-Jun YAN ;
China Biotechnology 2006;0(01):-
Lipases have catalytic active in both aqueous phase and the non-aqueous phase and have a wide range of application in various industrial areas.However,the high cost of lipase production has restricted its extensive use in industry.Solid state fermentation possesses many advantages,such as low requirement for devices,low energy consumption,low production cost,little pollution to environment and easily being popularized,which have made it an important means in microbial production of lipases.Owing to the rapidly increased energy cost and the people's awareness of environmental protection,the solid state fermentation technique,which was regarded as low-tech in the past,has regained attention and developed rapidly since the 1990s.The production of lipase by SSF technique was reviewed.Mainly contents describe its characteristics,including physical and chemical factors and bioreactors.
3.New principles in tumor antigens and their significance in future immunotherapies for lymphomas and other malignancies--editorial.
Xiao-Yan KE ; Jing WANG ; Xiao-Feng YANG
Journal of Experimental Hematology 2006;14(3):419-426
The molecular characterization of self-antigens expressed by human malignancies that are capable of elicitation of anti-tumor immune responses in patients has been an active field in hematology, oncology, and tumor immunology. More than 2000 tumor antigens have been identified. These significant progresses have led to the renaissance of tumor immunology and studies on novel anti-tumor immunotherapies in lymphomas, other hematologic malignancies and tumors. However, despite of the progress in the identification of these self-tumor antigens, current antigen-specific immunotherapies for tumors are far less satisfactory than that expected, which reflects the urgent need to improve our understanding on the basic principles underlying the selection of these self-tumor antigens. In order to develop more effective antigen-specific anti-tumor immunotherapies and to monitor the responses to these immunotherapies in patients with lymphomas and other malignancies, many additional questions need to be addressed. In this brief review, the progress in the identification of tumor antigens in lymphomas and other malignancies was outlined and the new principles of self-tumor antigens and their significance for future immunotherapies to these malignancies were summarized.
Antigens, Neoplasm
;
classification
;
immunology
;
therapeutic use
;
Autoantigens
;
classification
;
immunology
;
Hematologic Neoplasms
;
therapy
;
Humans
;
Immunotherapy
;
methods
;
trends
;
Lymphoma
;
immunology
;
therapy
;
Neoplasms
;
immunology
;
therapy
6.Advances in lymphangiogenesis and metastasis of tumor.
Xiao-chu YAN ; Dong-mei YU ; Feng-xuan LIU
Chinese Journal of Pathology 2005;34(6):370-372
Animals
;
Humans
;
Lymph Nodes
;
pathology
;
Lymphangiogenesis
;
physiology
;
Lymphatic Metastasis
;
Lymphatic Vessels
;
metabolism
;
pathology
;
Neoplasms
;
metabolism
;
pathology
;
Vascular Endothelial Growth Factor C
;
metabolism
;
physiology
;
Vascular Endothelial Growth Factor D
;
metabolism
;
physiology
7.Pharmacokinetic study of iguratimod in rats
Feng XIAO ; Zhaoyi YANG ; Shangxue YAN ; Wei WEI
Chinese Journal of Primary Medicine and Pharmacy 2008;15(6):-
ObjectiveTo study the pharmacokinetics of iguratimod in rats. MethodsThe concentration ofiguratirnod in the samples was determined by HPLC method. The pharmacokineties parameters were calculated withDAS softwrare. ResultsThe mainpharmacokineties parameters of normal group(6mg/kg) were as follows:t1/2Ke:3.56h, tpeak: 4.00h, Cmax : 8.87μg/ml, AUC0.24 : 74.76μg· ml-1·h-1. The main pharmacokineties parameters of threemodel groups(3,6,12mg/kg) were as follows: t1/2Ke: 4.54,3.20,3.17h, tpcak:3.83,3.83,4.67h,Cmax:3.84, 8.31,12.69μg/ml, AUC0.24 :40.21,76. 72,117.06μg·ml-1·h-1. Except Cmax and AUC, no significant differenceswere found between the three model groups. And the differences between normal group and model group were notsignificant. ConclusionThe pharmacokinetics of rats ks fit to one-compartment model.
8.One case of nasal septum chordoma.
Yan LIU ; Xin-yi LIU ; Xiao-feng ZHANG
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2012;47(6):514-515
Adult
;
Chordoma
;
Humans
;
Male
;
Nasal Septum
;
pathology
;
Nose Neoplasms
9.Effect of dexmedetomidine on acute kidney injury after cardiac valve replacement with cardiopulmonary bypass
Feng XUE ; Wei ZHANG ; Xiao ZHANG ; Yan JIANG ; Haichen CHU
Chinese Journal of Anesthesiology 2016;36(10):1171-1174
Objective To evaluate the effect of dexmedetomidine on acute kidney injury after cardiac valve replacement with cardiopulmonary bypass (CPB).Methods One hundred patients of both sexes with rheumatic heart disease,aged 32-64 yr,weighing 46-75 kg,of American Society of Anesthesiologists physical status Ⅱ or Ⅲ (New York Heart Association class Ⅱ or Ⅲ),scheduled for elective cardiac valve replacement with CPB,were divided into 2 groups (n =50 each) using a random number table:control group (group C) and dexmedetomidine group (group D).Dexmedetomidine was intravenously infused in a loading dose of 1 μg/kg over 10 min before induction of anesthesia followed by an infusion of 0.4 μg · kg-1 · h-1 until 24 h after operation in group D,while the equal volume of normal saline was given in group C.The urine output per hour during the postoperative 48 h period was recorded.At 6,12,24,36 and 48 h after operation,blood samples were collected from the median cubital vein for determination of serum creatinine levels.The development and severity of acute kidney injury were determined according to the urine output and serum creatinine level.Results Compared with group C,the incidence and severity of acute kidney injury were significantly decreased in the postoperative 48 h period in group D (P<0.05).Conclusion Dexmedetomidine infused in a loading dose of 1 μg/kg over 10 min before induction of anesthesia followed by an infusion of 0.4 μg · kg-1 · h-1 until 24 h after operation can reduce the development and severity of acute kidney injury after cardiac valve replacement with CPB in patients.
10.The Effect of the Simvastatin Administration on the Expression of Connective Tissue Growth Factor in Fibrotic Lungs of Rats
Yanhua FENG ; Li XIAO ; Hongguang WAN ; Yan DU ; Ying HE
Journal of China Medical University 2010;(9):719-723
Objective To explore the effect of the simvastatin administration on the expression of connective tissue growth factor (CTGF) in fihrotic lungs of rats. Methods The cats were treated with single intratracheal instillation of bleomycin (BLM) or instillation of the same volume of normal saline (NS) as a control. The administration of simvastatin(20 mg/kg)began once a day immediately or 7 days later after intratracheal BLM instillation respectively with the same volume of NS was given as a vehicle control. The rats were killed on day 7,14 and 28 respectively. Pathological alteration of lung tissue was observed hy HE staining and Masson staining. Hydroxyproline(HYP)content in lung tissue was used to determine the severity of pulmonary fibrosis. The expression of CTGF in lung tissue was exanfined by immunohistochem- istry staining and photodeusitometry. Results Histopathological changes of pulmonary fibrosis emerged gradually after the instillation of BLM. The expression level of CTGF was increased in lungs of rats after intratracheal instillation of BLM, compared with the control. The administration of simvastatin immediately or 7 days after intratracheal instillation of BLM, attenuated the histopathological changes of bleomycin- induced puhnonary fibrosis and prevented the increased expression of CTGF in lung tissue on day 28. Conclusion The adntinistration of simvastatin, immediately or 7 days after intratracheal BLM instillation, prevented the up-regulation of CTGF in fibrotic lungs of rats, which ntight be one of the mechanisms of the anti-fihrosis of simvastatin in lungs.